Press release
Psoriasis Clinical Trial Pipeline Analysis: 65+ Key Companies Shaping the Future of Psoriasis Therapeutics | DelveInsight
DelveInsight's Psoriasis Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline psoriasis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the psoriasis pipeline domain.Key takeaways from the Psoriasis Clinical Trial Landscape Report
• DelveInsight's psoriasis pipeline report depicts a robust space with 65+ active players working to develop 75+ pipeline therapies for psoriasis treatment.
• Key psoriasis companies such as Haisco Pharmaceutical Group, Seismic Therapeutic AU, Oruka Therapeutics, Inc., Arcus Biosciences, Usynova Pharmaceuticals, MetrioPharm, Can-Fite Biopharma, and others
• Promising psoriasis pipeline therapies in various stages of development include Piclidenoson, MP1032, HSK44459, S-4321, and others
Request a sample and discover the recent advances in psoriasis treatment drugs at: https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
What is Psoriasis?
Psoriasis is a chronic (long-lasting) disease in which the immune system becomes overactive, causing skin cells to multiply too quickly. Patches of skin become scaly and inflamed, most often on the scalp, elbows, or knees, but other parts of the body can be affected as well. The disorder can also affect the joints and eyes. Psoriasis has no cure and the disease waxes and wanes with flareups. Many patients with psoriasis develop depression as the quality of life is poor. There are several subtypes of psoriasis but the plaque type is the most common and presents on the trunk, extremities, and scalp. The condition tends to go through cycles, flaring for a few weeks or months, then subsiding for a while. Common triggers in people with a genetic predisposition to psoriasis include infections, cuts or burns, and certain medications.
Emerging Psoriasis Drug Profiles
Piclidenoson: Can-Fite Biopharma
Piclidenoson is a novel, robust anti-inflammatory first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug with an excellent safety profile demonstrating evidence of efficacy in Phase II and Phase III clinical studies. The drug's mechanism of action entails inhibition of the inflammatory cytokines interleukin 17 and 23 (IL-17 and IL-23) and the induction of apoptosis of patients' skin cell keratinocytes involved with the disease pathogenicity. Currently, the drug is in Phase III stage of its development for the treatment of psoriasis.
MP1032: MetrioPharm
MP1032 is an orally administered small molecule under clinical investigation for psoriasis treatment and is currently in Phase II stage of development.
Learn more about the novel and emerging psoriasis pipeline therapies at: https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
Recent Developments in the Psoriasis Clinical Trial Landscape
• In December 2025, Soligenix, Inc. announced extended results of its ongoing Phase IIa trial of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis.
• In September 2025, Oruka Therapeutics, Inc. announced interim data from its Phase I trial of ORKA-001, the Company's long-acting IL-23p19 antibody, in a late-breaking abstract at the European Academy of Dermatology and Venerology (EADV) Congress in Paris, France.
• In May 2025, Can-Fite BioPharma Ltd announced that it has raised USD 175 million in funding to advance its lead drug candidate Piclidenoson into Phase III studies for psoriasis.
Scope of the Psoriasis Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, and others
• Therapeutics Assessment By Molecule Type: Small molecule, Bispecific antibody, and others
• Key Psoriasis Companies: Haisco Pharmaceutical Group, Seismic Therapeutic AU, Oruka Therapeutics, Inc., Arcus Biosciences, MetrioPharm, Can-Fite Biopharma, and others
• Key Psoriasis Pipeline Therapies: Piclidenoson, MP1032, HSK44459, S-4321, and others
Dive deep into rich insights for new drugs for psoriasis treatment, visit https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
Table of Contents
1. Psoriasis Pipeline Report Introduction
2. Psoriasis Pipeline Report Executive Summary
3. Psoriasis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Psoriasis Pipeline Therapeutics
6. Psoriasis Pipeline: Late Stage Products (Phase III)
7. Psoriasis Pipeline: Mid Stage Products (Phase II)
8. Psoriasis Pipeline: Early Stage Products (Phase I)
9. Psoriasis Pipeline Therapeutics Assessment
10. Inactive Products in the Psoriasis Pipeline
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products in the Psoriasis Pipeline
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix
For further information on the psoriasis pipeline therapeutics, reach out at: https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Psoriasis Clinical Trial Pipeline Analysis: 65+ Key Companies Shaping the Future of Psoriasis Therapeutics | DelveInsight here
News-ID: 4502281 • Views: …
More Releases from DelveInisight Business Research
Short Bowel Syndrome Therapeutics Market (7MM) is expected to grow from USD 2,50 …
DelveInsight's "Short Bowel Syndrome Treatment Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of Short Bowel Syndrome, historical and forecasted epidemiology as well as Short Bowel Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Explore the intricate details of the Short Bowel Syndrome Treatment Market Report @ https://www.delveinsight.com/sample-request/short-bowel-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from Short Bowel Syndrome Market…
High-grade Glioma (HGG) Market is Projected to Grow Significantly by 2036 Owing …
The market dynamics for High-grade Glioma (HGG) are witnessing steady growth driven by the rising incidence of aggressive brain tumors, increasing demand for effective targeted therapies, and growing adoption of advanced immunotherapies and precision medicine approaches. Additionally, the launch of emerging therapies such as DB107-RRV (Denovo Biopharma), MDNA55 (Medicenna Therapeutics), EO2401 (Enterome), and others will further fuel the market.
DelveInsight, a leading market research firm, announces the release of its latest…
Down Syndrome Market is Projected to Boom by 2036 Owing to the Launch of Novel T …
The market dynamics for Down Syndrome is witnessing steady growth driven by the rising Disease Prevalence and Diagnosis Rates, Increasing Demand for Effective Supportive and Symptomatic Therapies, and Growing Preference for Personalized and Non-pharmacological Treatment Approaches. Additionally, the launch of emerging therapies such as AEF0217 (Aelis Farma), ACI-24.060 (AC Immune/Takeda), CTH120 (Connecta Therapeutics), and others will further fuel the market.
DelveInsight, a leading market research firm, announces the release of its…
Immune Thrombocytopenia Market Set for Significant Growth by 2036, Driven by Eme …
The Immune Thrombocytopenia market is expected to grow steadily across the 7MM during the forecast period (2026-2036), driven by increasing disease awareness, improving diagnostic capabilities, and the anticipated launch of emerging therapies such as Ianalumab (Novartis), Mezagitamab (Takeda), PF-06835375 (Pfizer), and Cevidoplenib (Genosco/Oscotec), and others. These novel therapies are expected to reshape the treatment landscape for this autoimmune hematological disorder.
DelveInsight's report, "Immune Thrombocytopenia Market Insight, Epidemiology, and Market Forecast-2036," provides…
More Releases for Psoriasis
Prevalence Of Psoriasis Driving Market Growth: A Key Catalyst Accelerating Psori …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Psoriasis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
Over the recent years, there has been a robust growth in the size of the psoriasis market. It is estimated to rise from $26.45 billion in 2024 to $28.93 billion in 2025, with a compound annual…
Psoriasis Vulgaris Market
Introduction
Psoriasis vulgaris, also known as plaque psoriasis, is the most common form of psoriasis, accounting for nearly 80-90% of all cases. It is a chronic autoimmune condition marked by red, scaly plaques that can cause significant physical discomfort and emotional distress. Affecting millions worldwide, psoriasis vulgaris is increasingly recognized as both a dermatological and systemic disease due to its association with arthritis, cardiovascular disease, and metabolic syndrome.
The global psoriasis vulgaris…
Major Growth Driver Identified in 2025 Psoriasis Market: Prevalence Of Psoriasis …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Psoriasis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the size of the psoriasis market has experienced a significant increase. It is projected to escalate from $26.56 billion in 2024 to $29.5 billion in 2025, reflecting a compound annual growth rate (CAGR)…
Prevalence Of Psoriasis Driving Market Growth: Key Factor Driving The Growth In …
The Psoriasis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Psoriasis Market Size During the Forecast Period?
The psoriasis market has seen rapid growth in recent years. It will increase from $26.56 billion in 2024 to $29.5 billion in 2025, at a…
Plaque Psoriasis to Hold 85% Share of Psoriasis Drugs Market through 2031
Psoriasis is a chronic inflammatory skin disease that occurs due to genetic disposition and environmental factors. Psoriasis is a systemic disease associated with psychological, metabolic, arthritic, and cardiovascular comorbidities. On an average, psoriasis affects around 2 - 3% of the population globally.
Plaque psoriasis, being the number one and most common indication, held nearly 85% share of the US$ 11.37 Bn psoriasis drugs market in 2021, with the market estimated to…
Global Psoriasis Market with Focus on Plaque Psoriasis: Outlook to 2020
Psoriasis is a chronic inflammatory skin disease primarily causing scaling and inflammation of skin, characterized by sharply demarcated, scaly, red skin lesions most often on the elbows, knees, scalps, hands and feet. It occurs when the body’s immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis has been majorly classified into Plaque psoriasis, Guttate psoriasis, Inverse psoriasis, Pustular psoriasis and Erytherodermic psoriasis. It…
